Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2023 | 03-2022 | 03-2021 | 03-2020 | 03-2019 | |
| Sales | 0 | 0 | 7,362 | 7,508 | 7,269 |
| Cost of Goods | N/A | N/A | 4,671 | 4,585 | 4,564 |
| Gross Profit | N/A | N/A | 2,691 | 2,924 | 2,705 |
| Operating Expenses | 15,543 | 20,367 | 22,092 | 17,730 | 12,556 |
| Operating Income | -15,543 | -20,367 | -18,731 | -14,222 | -9,287 |
| Interest Expense | 0 | 2 | 50 | 399 | 400 |
| Other Income | 950 | 225 | 35 | 74 | 24 |
| Pre-tax Income | -14,594 | -20,145 | -18,746 | -14,547 | -9,664 |
| Income Tax | N/A | N/A | N/A | -5 | 102 |
| Net Income Continuous | -14,594 | -20,145 | -18,746 | -14,541 | -9,766 |
| Net Income Discontinuous | -139 | 152 | -1,188 | N/A | N/A |
| Net Income | $-14,733 | $-19,993 | $-19,934 | $-14,541 | $-9,766 |
| EPS Basic Total Ops | -0.28 | -0.40 | -0.53 | -0.53 | -0.46 |
| EPS Basic Continuous Ops | -0.28 | -0.40 | -0.50 | -0.53 | -0.45 |
| EPS Basic Discontinuous Ops | 0.00 | 0.00 | -0.03 | N/A | N/A |
| EPS Diluted Total Ops | -0.28 | -0.40 | -0.53 | -0.53 | -0.46 |
| EPS Diluted Continuous Ops | -0.28 | -0.40 | -0.50 | -0.53 | -0.45 |
| EPS Diluted Discontinuous Ops | 0.00 | 0.00 | -0.03 | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | -0.28 | -0.40 | -0.52 | -0.50 | -0.50 |
| EBITDA(a) | $-15,543 | $-20,288 | $-18,369 | $-13,792 | $-7,968 |